Industry Reports
Top Biopharma Companies Show A Dip In Market Cap For Q3
The market capitalization of the top 20 biopharmaceutical businesses worldwide has decreased by 9.1%, from $3.45 trillion in Q2 2022 to $3.14 trillion in Q3 2022, as a result of growing generic competition and a decline in demand for...
Industry Reports
PharmaLytica Expo to aid in chalking out pharma industry’s $130 Billion growth story by 2030
The 8th edition of PharmaLytica Expo opened its doors to industry professionals at the Bombay Exhibition Centre, Mumbai. The event had a grand opening in the presence of key dignitaries Mr. K. G. Ananthakrishnan, Director General – OPPI, Mr....
Industry Reports
Vetter publishes first sustainability report
Vetter, a global leading Contract Development and Manufacturing Organization (CDMO), has published its first sustainability report. The report underpins the company commitment to sustainable action and covers three areas: Ecological Responsibility, Sustainable Economy, and Social Engagement. In doing so,...
Industry Reports
Dr. Reddys Says Russia Sales Booming As Big Pharma Retreats
While many western biopharma businesses have shied away from Russia since its invasion of Ukraine, some of those in India have stepped in to fill the hole by providing the Kremlin with medical supplies. Dr. Reddy's Laboratories has been...
Industry Reports
Commercializing Biopharmaceutical Innovation In A New Era
The new era in biopharmaceutical development promises to usher in a slew of breakthrough medicines, including cures for treatment options. More than 7,800 medications are in clinical development, spanning a wide variety of therapeutic categories from cancer to cardiovascular...
Industry Reports
Pfizer Shells Out $11.6 Bn. For Biohaven- Largest Since 2016
Pfizer will pay $11.6 billion for migraine medicine manufacturer Biohaven Pharmaceutical, signifying the company's largest acquisition since 2016, as it seeks to expand its inventory ahead of patent expiration dates for many cancer drugs.
Pfizer will gain access to Biohaven's...
Industry Reports
Japan Drug Lobby Asserts Pricing Scheme Driving Drug Crisis
For the first time in the week starting May 16th, Japan's three major pharmaceutical trade associations joined forces to call for changes to the government's drug pricing structure in order to prevent missing out on new drug innovation and...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
